Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content


34G Needle for Pen Injectors


Nanopass® 34G Pen Needle

Nanopass® 34G Pen Needles feature the world's thinnest double-tapered needle and a unique asymmetric bevel precisely engineered for smoother penetrations and less painful injections1 .


  • World's thinnest double tapered pen needle "34G"

  • Asymetric bevel

  • Slim double tapered shape2

Patented design for all pen injector applications

Engineered to reduce the pain of regular injections for diabetes and other chronic conditions, Nanopass® 34G Pen Needles feature a 22% thinner double-tapered needle and better flow than comparable 32G designs. Configured to fit most common pen injectors, Terumo Pharmaceutical Solutions’ asymmetric bevel lance limits pain by significantly reducing penetration resistance2.

Designed for the subcutaneous injection of therapeutics including insulin and human growth hormones, Nanopass® 34G Pen Needles offer the quality and supply reliability needed to meet drug developers’ toughest parenteral delivery challenges and product commercialization goals. 

Patient's comfort in mind

  • Asymmetric needle tip reduces skin trauma and pressure by cutting, not puncturing skin on penetration
  • 34G needle 22% thinner than 32G, decreasing probability of touching pain receptors in the skin
  • Optimized flow, less injection force than 32G needles (insulin)3

Engineered for automated environments

  • Individually packed and sealed in an ergonomic plastic case for automated assembly and easier patient handling

Regulatory and Quality Aspects

  • Radiation sterilization Sterility Assurance Level at least 10-6 
  • In compliance with applicable ISO standards and Pharmacopoeia 
  • Proven track record of reliable supply assured by global operating company

General specifications

​Nanopass® 34G Pen Needles are intended exclusively for pen injector applications.

Specification Description
Needle tip diameter34G
Needle length4 mm
Needle materialStainless steel X5CrNi 18-10
Individual packagingPolypropylene w/seal
Package100 pcs.
Shelf-life5 years

Global Solutions

Nanopass® 34G Pen Needle solutions are available to drug product manufacturers globally. For more information about product availability, specifications, and applicable standards, download our data sheet or contact your Terumo representative today.

Please note that some products may not be available in all regions, check with your local TERUMO Pharmaceuticals Solutions contact for details.
This product is also available for HCP professionals. Please visit the  Terumo Europe website.


Relevant product information


1 Basic study of Nanopass II (34G  4 mm) for pen-type injector. Asakura T., Seino H., 2013, Jpn J Med Pharm Sci 69(1):137-146. & Asakura T., 2013, Jpn J Med Pharm Sci 69(1):147-155  (Study conducted with patients injecting insulin) 
2 Patented Technology 
3 Based on research by Terumo Corporation in May 2017 

Let’s Find Your Best Solution

Innovation and creativity are central to Terumo Pharmaceutical Solutions’ value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies for all parenteral applications.

Contact Us

Didn't find your product?

Consult our products in our Product Index

Are you a pharmaceutical professional?

This information is intended for professionals in the pharmaceutical supply chain who are interested in primary packaging, injection components and medical devices from Terumo Pharmaceutical Solutions, for use in combination with their respective drug products (hereafter, pharmaceutical professionals). Please note that the product information contained on this website is exclusively addressed to pharmaceutical professionals. This product information is not for the general public, nor is it intended to be a substitute for professional medical advice or for the care that patients receive from their healthcare professionals. By accessing it, you (i) acknowledge having read and understood both the above message and our terms of use and, further, (ii) confirm that you do so in the capacity of a pharmaceutical professional.